PLUS1
0.0169
0.00235 (16.15%)
0.00235 (16.15%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
Small Cap Basic
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Boston Therapeutics Inc (QB) | BTHE | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Previous Close | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00235 | 16.15% | 0.0169 | 0.0169 | 0.0169 | 0.0169 | 0.01455 | 12:01:22 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.0122 | 0.0169 | 0.0047 | 27.81% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3 | 21,000 | $ 0.0169 | $ 355 | 16,275 | 0.0052 - 0.0332 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:56:29 | 5,000 | $ 0.0169 | USD |
Boston Therapeutics (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.88M | 111.13M | 43.38M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 606.00 | $ - | 0.00% | - | - |
Boston Therapeutics (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 6/08/2020 | 15:28 | Edgar (US Regulatory) | Annual Report (10-k) |
| 5/15/2020 | 16:56 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 5/15/2020 | 16:33 | Edgar (US Regulatory) | Amended Notification That Annual Report Will Be Submitted.. |
| 5/11/2020 | 17:15 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) |
| 5/11/2020 | 17:13 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) |
| 5/11/2020 | 17:11 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) |
| 4/14/2020 | 10:47 | Edgar (US Regulatory) | Current Report Filing (8-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BTHE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.01445 | 0.0169 | 0.012 | 0.0141267 | 4,933 | 0.00245 | 16.96% |
| 1 Month | 0.013 | 0.018 | 0.0115 | 0.0134721 | 15,288 | 0.0039 | 30.0% |
| 3 Months | 0.0159 | 0.0198 | 0.011 | 0.0136794 | 16,916 | 0.001 | 6.29% |
| 6 Months | 0.02255 | 0.028 | 0.00765 | 0.0140365 | 30,390 | -0.00565 | -25.06% |
| 1 Year | 0.0112 | 0.0332 | 0.0052 | 0.0147377 | 57,431 | 0.0057 | 50.89% |
| 3 Years | 0.057 | 0.1164 | 0.0052 | 0.0341299 | 52,917 | -0.0401 | -70.35% |
| 5 Years | 0.14 | 0.23 | 0.0052 | 0.0482387 | 48,178 | -0.1231 | -87.93% |
Boston Therapeutics (QB) Description
| Boston Therapeutics, Inc. (OTCQB: BTHE), headquartered in Lawrence, MA, is a leader in the field of designing drugs using complex carbohydrates. The Company's product pipeline is focused on developing and commercializing therapeutic molecules for diabetes, including: BTI-320, a non-systemic chewable compound designed to reduce post-meal glucose elevation; IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia; and SUGARDOWN(R), an OTC dietary supplement designed to lower post-meal sugar spike. More information on BTHE is available at www.bostonti.com. |
